丹参干预肿瘤和缺血性疾病血管生成研究进展-天津中草药杂志社.PDF

中草药 Chinese Traditional and Herbal Drugs 第46 卷 第9 期 2015 年5 月 ·1399 · 丹参干预肿瘤和缺血性疾病血管生成研究进展 1, 2, 3 1 1, 2, 3* 1 1, 2, 3 1 王爱云 ，陶 丽 ，陆 茵 ，林依平 ，陈文星 ，周 梁 1. 南京中医药大学药学院，江苏 南京 210023 2. 江苏省中药药效与安全性评价重点实验室，江苏 南京 210023 3. 江苏省中医药防治肿瘤协同创新中心，江苏 南京 210023 摘 要：血管异常增生的疾病如肿瘤治疗要抗血管生成，而缺血性疾病的治疗要促血管生成。肿瘤与缺血后新生血管主要区 别在于血管的成熟度和稳定性不同，而血管生成是个复杂的过程。活血化瘀代表中药丹参普遍应用于肿瘤和缺血性疾病。综 述近年来对丹参及其水溶性和脂溶性成分影响血管生成的研究进展，丹参各种成分表现出抗血管生成和促血管生成双重调控 作用。丹参对血管生成表现出的调控效应可能与实验条件的不同，丹参成分的多样性，血管生成的复杂性，以及不同病理状 态下体内分布的差异有关系。 关键词：丹参；血管生成；肿瘤；缺血性疾病；丹参素；丹酚酸B ；丹参酮 中图分类号：R285 文献标志码：A 文章编号：0253 - 2670(2015)09 - 1399 - 06 DOI: 10.7501/j.issn.0253-2670.2015.09.025 Research progress on intervention by p j o et o on angiogenesis of tumor and ischemic disease 1, 2, 3 1 1, 2, 3 1 1, 2, 3 1 WANG Ai-yun , TAO Li , LU Yin , LIN Yi-ping , CHEN Wen-xing , ZHOU Liang 1. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China 2. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing 210023, China 3. Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine for Prevention and Treatment of Tumor, Nanjing 210023, China Abstract: Diseases with excessive angiogenesis such as tumors need to be treated with anti-angiogenesis agents, while ischemic diseases need to be treated with pro-angiogenesis agents. p j o et o, the representative drug which promotes circulation and resolves clots, was widely used in treating tumors and ischemic diseases. This review focused on the current research on the angiogenic effect of p j o et o and its water-soluble or fat-soluble components. It was found that there are some controversy reports. Bo